Frequency of administration is decided by the treating physician
Im 35 years old, Id get up in the morning and go downstairs, grab a cup of coffee, be in my kitchen, forget why I was in my kitchen, and just this massive brain fog and forgetfulness, said Heafey
*Correspondence: Weici Wang [email protected] Ye [email protected] These authors have contributed equally to this work and share first authorship This article was submitted to Infectious Diseases - Surveillance, Prevention and Treatment, a section of the journal Frontiers in Public Health Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
These approaches have led to significant weight loss with the dual GLP-1/glucagon receptor agonist survodutide (-13.5% with the 6-mg dose at 76 weeks in a phase 3 SYNCHRONIZE-1 trial) [16] , the dual GLP-1 receptor agonist and GIP antagonist Maridebart cafraglutide (known as MariTide) (-12.3% to -16.2% across different doses at 52 weeks in a phase 2 trial) [17] or the triple GLP-1/GIP/glucagon receptor agonist retatrutide (-24.2% with the 12-mg dose at 48 weeks in a phase 2 trial) [18]
%20(1).png)
